CN105769760B - 布帕伐醌注射液及其制备方法 - Google Patents
布帕伐醌注射液及其制备方法 Download PDFInfo
- Publication number
- CN105769760B CN105769760B CN201610231324.5A CN201610231324A CN105769760B CN 105769760 B CN105769760 B CN 105769760B CN 201610231324 A CN201610231324 A CN 201610231324A CN 105769760 B CN105769760 B CN 105769760B
- Authority
- CN
- China
- Prior art keywords
- buparvaquone
- injection
- antioxidant
- preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229950008349 buparvaquone Drugs 0.000 title claims abstract description 59
- KLLIVCPQDTYMLC-HDJSIYSDSA-N chembl292009 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1CC1=C(O)C(=O)C2=CC=CC=C2C1=O KLLIVCPQDTYMLC-HDJSIYSDSA-N 0.000 title claims abstract description 59
- 238000002347 injection Methods 0.000 title claims abstract description 56
- 239000007924 injection Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 15
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 6
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims description 13
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 9
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical class CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 abstract description 6
- 235000000396 iron Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- 201000008680 babesiosis Diseases 0.000 description 5
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241001466447 Babesia gibsoni Species 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- JBFUOGRCSLVENL-UHFFFAOYSA-N O=C1C2=CC=CC=C2C(=O)C(O)=C1C1CCCCC1 Chemical compound O=C1C2=CC=CC=C2C(=O)C(O)=C1C1CCCCC1 JBFUOGRCSLVENL-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000010409 ironing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950004865 parvaquone Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610231324.5A CN105769760B (zh) | 2016-04-14 | 2016-04-14 | 布帕伐醌注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610231324.5A CN105769760B (zh) | 2016-04-14 | 2016-04-14 | 布帕伐醌注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105769760A CN105769760A (zh) | 2016-07-20 |
CN105769760B true CN105769760B (zh) | 2018-10-12 |
Family
ID=56396489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610231324.5A Active CN105769760B (zh) | 2016-04-14 | 2016-04-14 | 布帕伐醌注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105769760B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1620283A (zh) * | 2000-07-28 | 2005-05-25 | 法马索尔股份有限公司 | 微溶解或难溶解的活性成分的分散体的配制 |
EP2433624B1 (en) * | 2010-09-23 | 2013-08-21 | Bimeda International Pharmaceuticals Limited | Use of buparvaquone for controlling mites parasitising honeybees |
-
2016
- 2016-04-14 CN CN201610231324.5A patent/CN105769760B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1620283A (zh) * | 2000-07-28 | 2005-05-25 | 法马索尔股份有限公司 | 微溶解或难溶解的活性成分的分散体的配制 |
EP2433624B1 (en) * | 2010-09-23 | 2013-08-21 | Bimeda International Pharmaceuticals Limited | Use of buparvaquone for controlling mites parasitising honeybees |
Non-Patent Citations (3)
Title |
---|
Buparvaquone is active against Neospora caninum in vitro and in experimentally infected mice;Joachim Müller et al.;《International Journal for Parasitology: Drugs and Drug Resistance》;20150214;第5卷(第1期);第17页右栏第1段 * |
Buparvaquone mucoadhesive nanosuspension: preparation,optimisation and long-term stability;R.H. Muller et al.;《International Journal of Pharmaceutics》;20020221;第237卷(第1-2期);第151-162页 * |
Clinical efficacy and plasma concentrations of two formulations of buparvaquone in cattle infected with East Coast fever (Theileria parva infection);G.R. Muraguri er al.;《Research in Veterinary Science》;20060831;第81卷(第1期);第120页左栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN105769760A (zh) | 2016-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gould et al. | Nicotine enhancement of contextual fear conditioning | |
CN105267142B (zh) | 一种恩诺沙星注射液及其制备方法 | |
Edy et al. | Formulation and evaluation of hydrogel containing Tagetes erecta L. Leaves etanolic extract | |
Rawal Jatin et al. | Determination of bioactive components of Cynodon dactylon by GC-MS analysis & it’s in vitro antimicrobial activity | |
CN105769760B (zh) | 布帕伐醌注射液及其制备方法 | |
US20200384051A1 (en) | Herbal formulations of carnivorous plants and methods for treating inflammation | |
JP2015526463A (ja) | 改善されたダプトマイシン注射用製剤 | |
CN103143019A (zh) | 一种治疗猪传染性胸膜肺炎及呼吸道混合感染的复方制剂及其制备方法 | |
CN103432150B (zh) | 增效酒石酸泰乐菌素可溶性粉的复方药物 | |
CN105250333A (zh) | 一种抗菌润肤的药物组合物及其制备方法 | |
CN105125484A (zh) | 一种无痛化的多西环素注射液及其制备方法 | |
EP1283047A1 (de) | Methode zur herstellung einer bioaktiven substanz aus blutserum | |
KR101055689B1 (ko) | 봉독을 포함하는 젖소 유방염 주입제의 약제학적 조성물 | |
CN104906039A (zh) | 一种替米考星注射用混悬剂及其制备方法 | |
CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
AU2016390920B2 (en) | New use of isoquinoline derivatives for diabetic wound healing | |
CN110115756A (zh) | 一种具有抗菌、祛痘作用的精华液 | |
CN103405466B (zh) | 复方增效酒石酸泰乐菌素 | |
CN103405463A (zh) | 增效酒石酸泰乐菌素可溶性粉的复方药物制备方法 | |
CN103405465A (zh) | 用于治疗畜禽呼吸系统感染的药物的制备方法 | |
JPS6383022A (ja) | 獣医用治療剤 | |
BR102017006986A2 (pt) | composição farmacêutica de fenol injetável para o tratamento da espasticidade focal e processo de obtenção | |
WO2001058464A1 (fr) | Forme posologique d'ivermectine a dispersion aqueuse utilisee pour soigner ectoparasitose et endoparasitose | |
WO2016119089A1 (zh) | 一种治疗艾滋病的药物及其制备方法 | |
CN103405464B (zh) | 用于治疗畜禽呼吸系统感染的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210111 Address after: 570145 room 1506, Yusha international, 11-8 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee after: Quanku (Hainan) Intellectual Property Operation Co.,Ltd. Address before: 050200 No.114 Changsheng street, high tech Development Zone, Luquan City, Shijiazhuang City, Hebei Province Patentee before: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210128 Address after: 050200 No.114 Changsheng street, Luquan Development Zone, Shijiazhuang City, Hebei Province Patentee after: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Address before: 570145 room 1506, Yusha international, 11-8 Yusha Road, Longhua District, Haikou City, Hainan Province Patentee before: Quanku (Hainan) Intellectual Property Operation Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160720 Assignee: HEBEI GREENLAND ANIMAL PHARMACEUTICAL Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002827 Denomination of invention: Bupavalquinone injection and its preparation method Granted publication date: 20181012 License type: Common License Record date: 20240314 Application publication date: 20160720 Assignee: Hebei jianjiale duck industry Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002825 Denomination of invention: Bupavalquinone injection and its preparation method Granted publication date: 20181012 License type: Common License Record date: 20240313 Application publication date: 20160720 Assignee: Shijiazhuang Huifeng Animal Health Products Co.,Ltd. Assignor: HEBEI KEXING PHARMACEUTICAL Co.,Ltd. Contract record no.: X2024980002822 Denomination of invention: Bupavalquinone injection and its preparation method Granted publication date: 20181012 License type: Common License Record date: 20240313 |